Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|July 20, 2015

Baxter Recalls IV Solution for Insect in Bag

Baxter has initiated a voluntary recall of two lots of IV solutions due to the potential presence of particulate matter.

Baxter International Inc. announced on July 17 that it is voluntarily recalling two lots of intravenous (IV) solutions to the hospital/user level due to the potential presence of particulate matter.

The particulate matter in each case was determined to be an insect and was identified as a result of a customer complaint, the company reports. The matter was identified prior to patient administration and there have been no adverse events associated with this issue reported to Baxter.

This recall affects two lots of 0.9% sodium chloride injection, USP, 50 mL VIAFLEX Plastic Container, a product intended for intravenous use as a source of water and electrolytes. The lots being recalled were distributed to customers and distributors in the United States between Oct. 7, 2014 and July 14, 2015.

Source: Baxter International

 

 


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.